Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

There is also pembrolizumab, but this agent has to be given intravenously, potentially exposing the patient to more toxicity ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Bicycle Therapeutics plc, a company specializing in developing therapeutic solutions based on its proprietary bicyclic peptide technology, revealed significant data updates across its zelenectide ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS mutant NSCLC. A total of 20 ...